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Abstract Two sodium-dependent vitamin C transporters,
hSVCT1 and hSVCT2, were cloned from a human kidney
cDNA library. hSVCT1 had a 1797 bp open reading frame
encoding a 598 amino acid polypeptide. The 1953 bp open
reading frame of hSVCT2 encoded a 650 amino acid polypeptide.
Using a Xenopus laevis oocyte expression system, both
transporters were functionally expressed. By Eadie-Hofstee
transformation the apparent Km of hSVCT1 for ascorbate was
252.0 WM and of hSVCT2 for ascorbate was 21.3 WM. Both
transporters were sodium-dependent and did not transport
dehydroascorbic acid. Incubation of oocytes expressing either
transporter with phorbol 12-myristate 13-acetate (PMA) in-
hibited ascorbate transport activity. Availability of the human
transporter clones may facilitate new strategies for determining
vitamin C intake.
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1. Introduction
Ascorbic acid (ascorbate, vitamin C) is essential for human
health. Most mammals synthesize ascorbate, but human and
non-human primates are unable to synthesize and must ingest
ascorbate [1,2]. The known enzymatic roles of vitamin C in-
clude collagen hydroxylation, carnitine biosynthesis, and for-
mation of the catecholamine norepinephrine [2,3]. Other stud-
ies have emphasized the role of ascorbic acid as a chemical
electron donor or antioxidant [4,5].
Ascorbate accumulation in tissues occurs by two general
pathways [6]. In one pathway, ascorbate is oxidized extracel-
lularly to dehydroascorbic acid and transported via glucose
transporter isoforms GLUT1 and GLUT3 [6,7]. Once inter-
nalized dehydroascorbic acid is rapidly reduced by glutare-
doxin and other proteins to ascorbate [8^11]. The dehydroas-
corbic acid pathway is dependent on substrate formation, as
the substrate is not always present. In another distinct path-
way, ascorbate is transported as such in a sodium-dependent
manner [6,12]. In humans the ascorbate pathway is dependent
on substrate availability via diet.
In rats two sodium-dependent ascorbate transport proteins,
rSVCT1 and rSVCT2, were recently cloned [13]. Humans,
unlike rats, cannot make ascorbate, and the characterization
of the human transporter is therefore necessary and could
have implications for dietary recommendations. In this paper
we have cloned and expressed two human ascorbate trans-
porters, hSVCT1 and hSVCT2.
2. Materials and methods
2.1. Cloning and sequencing of human transporters hSVCT1 and
hSVCT2
Full length human hSVCT1 and hSVCT2 clones were generated by
polymerase chain reaction (PCR) screening of a Marathon Ready
kidney cDNA library (Clontech) [14]. PCR products were puri¢ed
by agarose gel electrophoresis and cloned into pGEM-T Easy vectors
(Promega). Double strand sequence analysis of three hSVCT1 and
three hSVCT2 clones was performed to rule out ambiguities or
PCR-introduced mutations.
2.2. cRNA synthesis of hSVCT1 and hSVCT2
hSVCT1 and hSVCT2 were linearized prior to in vitro transcrip-
tion. Capped cRNA was synthesized using the mMessage mMachine
kit (Ambion). The RNA integrity, size and concentration were meas-
ured by agarose gel electrophoresis.
2.3. Oocyte isolation and injection
Oocytes were isolated from Xenopus laevis sexually mature females
[7,15]. Isolated oocytes were injected using a Nanoject II injector
(Drummond Scienti¢c). Injection volumes were 36 nl and cRNA con-
centrations 1 ng/nl. Sham oocytes were injected with 36 nl sterile
water. Experiments were conducted 3 days post-injection.
2.4. Ascorbate transport
Ascorbate transport was measured as previously described for glu-
cose transporters [7]. Brie£y, 10^15 oocytes were incubated with
[14C]ascorbate (NEN Life Science Products, 8.0 mCi/mmol) at 23‡C
in OR-2 (5 mM HEPES, 82.5 mM NaCl, 2.5 mM KCl, 1 mM MgCl2,
1 mM Na2HPO4, 100 Wg/ml gentamicin, pH 7.8). Oocytes were then
rapidly washed four times with ice-cold phosphate bu¡ered saline and
lysed in 200 Wl 10% SDS. Internalized radioactivity was measured by
scintillation spectroscopy. For transport in the absence of Na, equi-
molar choline chloride was used instead of NaCl. When used, dehy-
droascorbic acid was synthesized as described [6].
PMA, dibutyryl cyclic (dc) AMP and ascorbate were purchased
from Sigma Chemical Co. Other reagents used were of the highest
chemical grade.
2.5. Statistical and kinetic calculations
The data are expressed as arithmetic mean þ S.D. of 10^15 oocytes
at each data point. Transport kinetics were calculated using Linewea-
ver-Burk and Eadie-Hofstee transformations.
3. Results
3.1. Cloning of the human vitamin C transporter hSVCT1
A BLAST (basic local alignment search tool) search with
rSVCT1 revealed it shares 95% identity with the human nu-
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cleobase transporter 3 (YSPL3) [16]. YSPL3 was classi¢ed
based on its 31% similarity to nucleobase transporter 1
(YSPL1).
Using PCR primers for YSPL3, a human kidney cDNA
library was screened. An 1800 bp PCR product was cloned
and three clones were sequenced. The sequences of the three
clones were identical. Sequence analysis revealed a 1797 bp
open reading frame, encoding a predicted 598 amino acid
Fig. 1. Nucleotide sequence of human hSVCT1 with the predicted amino acid sequence. Shown are predicted transmembrane segments (gray
shade), protein kinase C phosphorylation motifs (underlined), protein kinase A motif (bold), and ASN- glycosylation sites (boxed).
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polypeptide (Fig. 1). There were 41 nucleotide di¡erences be-
tween the new clone and YSPL3. A simple modular architec-
tural research tool (SMART) analysis of the predicted poly-
peptide identi¢ed 12 transmembrane segments consistent with
transport proteins [17]. The new clone was termed hSVCT1
(accession number AJ 269477).
3.2. Cloning of the human vitamin C transporter hSVCT2
A BLAST search with rSVCT2 identi¢ed YSPL2 as a pos-
sible human homolog. YSPL2 was 96% identical to rSVCT2
but only 31% similar to YSPL1. Using PCR primers for
YSPL2, a human kidney cDNA library was screened. A
2000 bp PCR product was cloned and three clones were se-
quenced. Sequence analysis identi¢ed a 1950 bp open reading
frame, encoding a predicted 650 amino acid polypeptide.
There was no sequence di¡erence between the new clones
and YSPL3. The clones were termed hSVCT2 (accession num-
ber AJ 269478).
3.3. Functional expression of hSVCT1 and hSVCT2 in
X. laevis oocytes
To investigate the functional properties of hSVCT1, cRNA
was injected into X. laevis oocytes. Xenopus oocytes lack en-
dogenous ascorbate transporters and sham-injected oocytes
did not accumulate detectable levels of [14C]ascorbate (Fig.
2A,B). As seen in Fig. 2A, hSVCT1-injected oocytes exhibited
a 100-fold increase in ascorbate transport. Transport was so-
dium-dependent, indicated by loss of transport in the presence
of choline. Dehydroascorbic acid was not transported by
hSVCT1.
Oocytes expressing hSVCT2 transporters also transported
ascorbate in a sodium-dependent manner (Fig. 2B). Addition
of excess unlabelled ascorbate inhibited [14C]ascorbic acid ac-
cumulation, con¢rming that ascorbate accumulation was not
due to di¡usion. Similar to hSVCT1, hSVCT2 did not trans-
port dehydroascorbic acid.
3.3. Ascorbate transport kinetics
To examine the kinetics of ascorbic acid transport, oocytes
expressing hSVCT1 transporters were incubated with increas-
ing concentrations of [14C]ascorbate. Ascorbate uptake was
saturable with an apparent Km of 233.8 WM and Vmax of
13.7 pmol/min/oocyte calculated by Lineweaver-Burk trans-
formation. By Eadie-Hofstee transformation the Km was
252.0 WM and Vmax was 15.8 pmol/min/oocyte.
Oocytes expressing hSVCT2 were also incubated with in-
creasing ascorbate concentrations. hSVCT2 transport con-
formed to simple Michaelis-Menten kinetics (Fig. 3B). The
calculated apparent Km for ascorbate from the double recip-
rocal plot was 22.6 WM, and Vmax was 0.2 pmol/min/5 oocytes.
The Km by Eadie-Hofstee transformation was 21.3 WM and
Vmax was 0.2 pmol/min/5 oocytes.
3.4. E¡ect of PMA and dcAMP on hSVCT1 and hSVCT2
A SMART pattern analysis search of hSVCT1 and
hSVCT2 identi¢ed ¢ve possible protein kinase C phosphoryl-
ation sites for hSVCT1 (Fig. 1), and six for hSVCT2 (not
shown). Analysis also identi¢ed a probable cyclic AMP phos-
phorylation motif in hSVCT1 (Fig. 1).
To test the possible signi¢cance of these motifs, oocytes
expressing hSVCT1 were incubated with the protein kinase
C stimulator PMA. This resulted in a 10-fold decrease in
ascorbate accumulation (Table 1). The e¡ect on PMA on
hSVCT2 was also signi¢cant with a 50% decrease in ascorbate
accumulation. These ¢ndings indicate both hSVCT1 and
hSVCT2 were sensitive to phorbol 12-myristate 13-acetate.
The cyclic AMP analog dcAMP had no signi¢cant e¡ect on
ascorbate uptake in oocytes expressing either transporter.
4. Discussion
In this study we cloned and functionally expressed the hu-
man vitamin C transporters hSVCT1 and hSVCT2. Based on
homology, hSVCT1 and hSVCT2 were identi¢ed as nucleo-
base transporters YSPL3 and YSPL2, respectively [14]. The
sequence analysis of hSVCT1 identi¢ed di¡erences between it
and YSPL3. These di¡erences may have resulted in a non-
functional YSPL3 clone. Although the hSVCT2 and YSPL2
clones were identical, YSPL2 did not have a functional com-
ponent [14].
The kinetic data concerning the Km for hSVCT2 of 22.2 WM
are consistent with plasma and tissue distribution of vitamin
C and localization of SVCT2. The wide tissue distribution of
rSVCT2 and YSPL2 implicates hSVCT2 as the cellular ascor-
bate transporter [13,14]. In humans, plasma concentration of
vitamin C as a function of dose is tightly controlled. At daily
Fig. 2. Functional expression of hSVCT1 (A) and hSVCT2 (B) in
Xenopus oocytes. Oocytes were incubated for 60 min with 100 WM
[14C]ascorbate (AA); choline and 100 WM [14C]ascorbate; 2 mM un-
labeled AA and 100 WM [14C]ascorbate; 500 WM [14C]dehydro-
ascorbic acid (DHA). Sham-injected oocytes (E) were incubated
with 100 WM [14C]ascorbate or 500 WM [14C]DHA.
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vitamin C doses of 200^250 mg, obtainable by eating ¢ve
fruits and vegetables, plasma vitamin C concentration is
80% saturated and is approximately 65^70 WM [2,18].
Steady-state plasma vitamin C concentration probably does
not exceed 100 WM despite ingestion of many grams of vita-
min C [18,19]. At plasma concentrations of approximately 60
WM, tissues appear to be saturated with vitamin C [18]. A Km
of 22.2 WM for hSVCT2 is concordant with these observations
and with observed sodium-dependent ascorbate transport in
human cells [12].
The Km for hSVCT1 of 237.3 WM was approximately 10-
fold higher that than for hSVCT2. Explanations of these ob-
servations might be di¡erent tissue distributions of the two
transporters and available vitamin C concentrations in the
di¡erent tissues. Because Northern blot analyses of rSVCT1
and YSPL3 localized their distribution to the small intestine,
kidney and liver [13,14], the primary role of hSVCT1 may be
in intestinal absorption and renal tubular reabsorption of vi-
tamin C. After ingestion of 100 mg of vitamin C, an amount
readily obtained from a meal containing fruits and vegetables,
it is possible that intraluminal intestinal concentrations of
vitamin C could be 200 WM. Although the renal tubule con-
Fig. 3. Ascorbate concentration-dependent transport in Xenopus oocytes. Oocytes expressing hSVCT1 (A) or hSVCT2 (B) were incubated for
15 and 60 min, respectively, with 0^850 WM [14C]ascorbate. Internalized radioactivity was measured as described in Section 2. Insets are Line-
weaver-Burk and Eadie-Hofstee transformations of the data.
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centration of vitamin C is unknown, it may be higher than the
vitamin C plasma concentration due to reabsorption of so-
dium and water in the tubule before the site of vitamin C
reabsorption. For these reasons, it can be predicted that the
Km of the vitamin C transporter in intestine and kidney will
be higher than that of hSVCT2. Indirect evidence supporting
the validity of the Km calculation for hSVCT1 is that bioavail-
ability of vitamin C is nearly complete at doses of 200 mg
[18,19], when intraluminal intestinal vitamin C concentration
could be as high as 0.5 mM.
Intestinal and tissue transport plays an essential role in
developing recommendations for vitamin C intake [2]. With
the availability of the human transporter clones, it may be-
come possible in the near future to consider recommendations
for vitamin C intake in relation to normal or aberrant trans-
porter function. Intake guidelines might then account for in-
dividuals with decreased transporter number or functionally
impaired transporters due to mutations or inappropriate reg-
ulation. For example, our preliminary studies of the possible
role of the protein kinase C stimulator phorbol myristate ace-
tate show that it inhibits hSVCT1 and hSVCT2 transport
activity. These data may provide insight into the role of pro-
tein kinase C as a regulator of hSVCT1 and hSVCT2. Studies
to consider variations in transport function and subsequent
e¡ect on vitamin absorption and distribution may have con-
siderable implications for dietary recommendations.
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Table 1
E¡ect of included PMA and dcAMP on ascorbate transport
Conditions hSVCT1
(pmol/h/oocyte)
hSVCT2
(pmol/h/5 oocytes)
None 198.2 þ 27.0 10.87 þ 0.3
PMA 17.5 þ 3.7 5.9 þ 1.6
dcAMP 141.9 þ 37.8 10.6 þ 1.8
Xenopus oocytes injected with hSVCT1 or hSVCT2 cRNA were in-
cubated with PMA (100 nM) or dcAMP (100 WM) for 60 min and
100 WM [14C]ascorbate. Ascorbate transport was measured as de-
scribed in Section 2.
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